Scientists reveal new insights and possible solutions for opioid epidemics using machine

September 13, 2017

Mount Sinai researchers have identified unique structural, biological and chemical insights in the way different opioid drugs activate the receptors and specific signaling pathways responsible for the drug's beneficial and adverse effects, according to a study to be published in Nature's Scientific Reports.

Opioid overdoses are the leading cause of in the United States. The findings of this study may provide a blueprint for designing improved painkillers.

"These new insights will provide a roadmap to develop a new class of drugs that are non-addictive and less harmful for patients," said Marta Filizola, PhD, Professor of Pharmacological Science and Professor of Neuroscience, Dean of The Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, and lead investigator of the study. "These insights may help us engineer new painkillers with reduced side effects, particularly respiratory depression. An alternative, non-addictive medication for chronic pain will help us combat the ongoing national crisis of addiction to opioid drugs and the devastating overdose epidemic deriving from it."

There have been many attempts to develop better opioid drugs but this has been largely unsuccessful due to incomplete understanding of the molecular signatures underlying the analgesic effects as opposed to the unwanted side effects. Potent opioid drugs that are often tied to fatal overdoses (e.g., heroin, fentanyl, or carfentanil) work by binding to in the nervous system. These drugs also provoke dopamine release, which causes euphoria leading to addiction and inhibits nerve cells in a region of the brain that regulates breathing, which can lead to respiratory depression and accidental death by overdose.

The therapeutic effect of is mainly attributed to mu-opioid receptor (MOR) activation leading to G protein signaling, meaning that the drug binds to the MOR receptor and causes a change in its molecular structure, which then activates a protein called the G protein. However, the drug's side effects have mostly been linked to a different process known as β-arrestin signaling, which plays a role in the regulation of these . To shed light on this, the researchers carried out molecular dynamics simulations in mouse models of MOR bound to a classical (morphine) or a potent G protein-biased agonist (TRV-130) that is currently being evaluated in human clinical trials for its potent analgesic effect with less and constipation than morphine.

The results of rigorous machine learning analyses of these simulations revealed unique structural, dynamic, and kinetic insights that have a direct utilization in the design of improved therapeutics targeting MOR.

Explore further: Receptor activation mechanism revealed for opioid and morphinan analgesics

Related Stories

Receptor activation mechanism revealed for opioid and morphinan analgesics

August 6, 2015
The most powerful analgesic and addictive properties of opiate alkaloids are mediated by the m-opioid receptor (mOR). As the receptor primarily responsible for the effects of opium, the mOR is one of the oldest drug targets ...

Trump declares opioid crisis a 'national emergency'

August 11, 2017
US President Donald Trump said Thursday that the opioid crisis in the United States constitutes a "national emergency" and pledged to step up efforts to fight the epidemic.

Chemical compound shows promise as alternative to opioid pain relievers

July 15, 2013
A drug targeting a protein complex containing two different types of opioid receptors may be an effective alternative to morphine and other opioid pain medications, without any of the side effects or risk of dependence, according ...

Opioid receptors outside the brain targeted in rats; new direction for painkillers

August 25, 2016
Opioid abuse is a growing public health crisis, affecting up to 36 million people worldwide. Many of these individuals first get hooked on prescription painkillers that target mu opioid receptors in the brain. A study in ...

Medicaid patients continue high prescription opioid use after overdose

August 22, 2017
Despite receiving medical attention for an overdose, patients in Pennsylvania Medicaid continued to have persistently high prescription opioid use, with only slight increases in use of medication-assisted treatment, according ...

Opioid misuse is increasing in middle-aged Britons – here's how it could cause an addiction crisis

July 31, 2017
The older we get, the more likely we are to suffer with long-term health problems. Life expectancy may be increasing, but so are the number of years we spend in ill health. In people aged 50 and over, the leading causes of ...

Recommended for you

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

Fentanyl drives rise in opioid-linked deaths in U.S.

August 31, 2017
(HealthDay)—Fentanyl, a synthetic narcotic, is a key player in America's continuing epidemic of opioid-related overdose deaths, two new studies report.

Eating triggers endorphin release in the brain

August 28, 2017
Finnish researchers have revealed how eating stimulates brain's endogenous opioid system to signal pleasure and satiety.

Cholesterol-lowering drugs may fight infectious disease

August 21, 2017
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty, providing protection against a whole host of infectious diseases, including typhoid fever, chlamydia, and malaria.

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

BubbaNicholson
1 / 5 (1) Sep 13, 2017
Opioid addiction is cured by taking 250mg of healthy adult male facial skin surface lipid by mouth one time. Cure is immediate and long lasting. Avoid the undetectable fumes from the pheromone as they cause distrust and other aversive emotions.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.